What is Avea?
Founded in 2021, Avea operates at the intersection of biotechnology and consumer health, specializing in the formulation of longevity-focused supplements. The company distinguishes itself through a rigorous, science-first approach to healthy aging, targeting the biological mechanisms of rejuvenation. By maintaining a dual presence in the United Kingdom and Switzerland, Avea effectively bridges the gap between cutting-edge European research and global consumer markets. Its market position is defined by a commitment to transparency and clinical efficacy, catering to a demographic increasingly focused on proactive health management and biological optimization.
How much funding has Avea raised?
Avea has raised a total of $5M across 1 funding round:
Angel/Seed
$5M
Angel/Seed (2023): $5M with participation from Maximon
Key Investors in Avea
Maximon
Maximon is a Swiss-based company builder that empowers entrepreneurs to create impactful, science-based, and scalable businesses focused on healthy aging and rejuvenation solutions.
What's next for Avea?
With this major enterprise-level funding, Avea is expected to scale its operational footprint and expand its product pipeline. The strategic focus will likely shift toward clinical validation of its existing supplement portfolio and the development of new, proprietary compounds designed to enhance cellular health. As the longevity sector matures, Avea's ability to integrate scientific rigor with scalable business models will be critical. The company is poised to leverage its current capital to strengthen its supply chain, enhance its digital direct-to-consumer platform, and potentially pursue strategic partnerships that align with its mission of extending the human healthspan through evidence-based interventions.
See full Avea company page
